Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eledon Pharmaceuticals

2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780%

These two growth stocks are attractive for investors seeking big upside in exchange for higher risk.

Barchart · Sep 23, 2025

2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360%

Analysts see enormous long-term potential in these two penny stocks.

Barchart · Aug 19, 2024

2 Penny Stocks Wall Street Expects to Soar Over 400%

These two penny stock companies, while risky and volatile, have the potential to generate massive returns, according to Wall Street's price forecasts.

Barchart · Jul 22, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga · Aug 1, 2022

Eledon Pharmaceuticals' Stock Gains As FDA Grants Orphan Drug Designation

Eledon Pharmaceuticals (NASDAQ: ELDN) received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation.

Benzinga · Jun 9, 2022

Earnings Outlook For Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Eledon Pharmaceuticals will report an earnings per share (EPS) of $-0.68.

Benzinga · May 11, 2022

A Preview Of Eledon Pharmaceuticals's Earnings

Eledon Pharmaceuticals (NASDAQ:ELDN) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that Eledon Pharmaceuticals will report an earnings per share (EPS) of $-0.83.

Benzinga · Mar 23, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Organisations

Food and Drug Administration

353 stories

Street

345 stories

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,838 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.